Features Partner Sites Information LinkXpress
Sign In
Demo Company

Endpoint Management and Adjudication Enhance Clinical Trials Platform

By BiotechDaily International staff writers
Posted on 17 Apr 2013
Print article
Endpoint adjudication management embedded within an electronic data capture platform optimizes the endpoint management and adjudication process, providing a collaborative and flexible workflow for all participants. Substantial cost effectiveness is achieved and cycle times reduced with a single, seamless system.

Merge Healthcare Incorporated (Chicago, IL, USA), a provider of clinical systems, recently added endpoint and adjudication management to its eClinical OS platform, providing end-to-end study support for trials of all sizes through a single platform.

“Merge eClinical has extensive experience working with the largest endpoint adjudication coordinating centers in the world. These relationships give us the unique experience to develop an endpoint adjudication module that is powerful, yet flexible enough to meet the complex requirements of all our clients. Merge’s latest enhancements to eClinical OS further our vision for delivering a unified solution for all data capture, processing, and return,” said Zaher El-Assi, general manager, eClinical solutions of Merge. “Through its single, easy-to-use interface, built-in study templates, libraries, and reports, and pay-as-you-go pricing, eClinical OS enables study sponsors and CROs to manage and run studies more efficiently than ever before.”

With Merge eClinical OS’ new Endpoint Adjudication Module, customers can: expedite cycle times with redaction tool and electronic compilation of source documents; auto-compile dossiers from source documents; reduce costs with fewer paper documents to track, ship, and review; Manage paired parallel, expert review and committee workflows; receive instant notifications that enable fast and efficient coordination; access reviewer assignments and dossiers from anywhere, at any time; and lastly, improve data quality through eCRFs and online edit checks.

“We began using eClinical OS towards the end of last year to manage and run our studies,” explained Thomas Engels, vice president of clinical affairs for CardioKinetix, Inc. (Menlo Park, CA, USA) “We’ve already seen enhanced efficiencies and improved productivity across the board, and are excited to begin using the new endpoint adjudication module to accelerate cycle times for adjudicating events.”

As a single, web-based system, Merge eClinical OS has the flexibility to support trials in any phase, and captures any type of data, from any source, over any modality. With a complete menu of clinical trial capabilities that can be mixed and matched, eClinical OS builds a solid foundation for each trial environment. Merge eClinical OS also has the scalability to grow if a trial increases in size, number, or complexity.

“We are obviously pleased by the positive customer response to eClinical OS,” stated Zaher El-Assi, general manager, eClinical Solutions of Merge. “Customer feedback has been integral to the product design, and I think it reflects a renewed focus on study efficiency. Merge eClinical OS places the control back in the users’ hands, resulting in shorter build times, faster implementation, and more cost effective trial design.”

Related Links:
Merge Healthcare

Print article



view channel
Image: Cryoelectron micrograph reconstruction of the Chikungunya virus (Photo courtesy of the Washington University School of Medicine).

Broadly Neutralizing Antibodies Protect Mice from Alphavirus Infection

While screening a panel of mouse and human monoclonal antibodies (MAbs) that had been raised against Chikungunya virus, researchers identified several with inhibitory activity against multiple other arthritogenic... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.